TDOC
Teladoc Health, Inc. [TDOC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TDOC Stock Summary
Top 10 Correlated ETFs
TDOC
Top 10 Correlated Stocks
TDOC
In the News
Investor Alert: 3 Red-Hot Opportunities You Can't Afford to Miss
Among thousands of stocks, the article lists three companies that have defied expectations and emerged as industry titans. They are poised to shape the future of healthcare, entertainment, and consumer technology.
The 5 Best Healthcare Stocks to Buy Now: September 2023
In today's dynamic market, many investors are paying attention to the healthcare sector. The segment is known for its resilience and potential for growth.
3 Absurdly Discounted Stocks That Are Too Cheap to Ignore
Teladoc, Disney, and PayPal are all leaders in their industries. Yet, the shares of all three are trading near multi-year lows.
4 Encouraging Trends for Teladoc Health
Teladoc Health's business has been slowing down, but revenue still increased 10% last quarter. The number of virtual visits hasn't fallen off a cliff despite the economy's return to normal.
5 Meme Stocks to Sell Immediately, According to AI
Last week, I revealed MarketMaster AI , a set of deep learning AI algorithms designed to beat the market. The system was flashing warning signals like a hyperactive lifeguard on duty.
A Bull Market Is Coming: 2 Beaten-Down Stocks to Buy and Hold
Teladoc's solid position in telemedicine, improving bottom line, and strong margins make a solid case for the stock. Tandem Diabetes Care develops cutting-edge insulin pumps for diabetes patients, an area with plenty of white space.
Buy Teladoc: AI Will Likely Spur Healthcare Deflation
Aging demographics and rising healthcare costs are major concerns for the global economy. Artificial Intelligence has the potential to significantly reduce healthcare costs and improve diagnosis and treatment plans. Teledoc, in partnership with Microsoft, is well-positioned to utilize AI and become a leader in bringing down healthcare costs.
7 Dirt-Cheap Stocks to Buy in August
The allure of high-potential dirt-cheap stocks often tempts those looking for the next big win. This year has seen some market sectors skyrocket while others remain in the shadows, with untapped potential.
2 Stocks With Solid Earnings Report to Buy Right Now
After a challenging few years, Teladoc's bottom line and margins are moving in the right direction. Roku is seeing its revenue growth rebound and expenses drop thanks to a recovering economy.
Why Teladoc Health Could Be an Extremely Underrated Buy
Teladoc's stock gained momentum since it released an encouraging earnings report last week. The company is no longer incurring hefty impairment losses, as its bottom line has been improving.
TDOC Financial details
TDOC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 6.35 | 7.7 | 12.09 | 12.95 | 14.91 | |
| Net income per share | -1.47 | -1.38 | -5.36 | -2.73 | -84.6 | |
| Operating cash flow per share | -0.07 | 0.42 | -0.59 | 1.24 | 1.17 | |
| Free cash flow per share | -0.2 | 0.26 | -0.88 | 0.83 | 0.1 | |
| Cash per share | 7.27 | 7.2 | 8.69 | 5.71 | 5.69 | |
| Book value per share | 15.39 | 14.11 | 175.49 | 102.24 | 14.29 | |
| Tangible book value per share | 0.43 | 0.59 | -7.94 | -2.35 | -3.73 | |
| Share holders equity per share | 15.39 | 14.11 | 175.49 | 102.24 | 14.29 | |
| Interest debt per share | 6.73 | 6.95 | 16.86 | 8.67 | 9.89 | |
| Market cap | 3.26B | 6.01B | 18.1B | 14.41B | 3.82B | |
| Enterprise value | 3.25B | 5.97B | 18.83B | 14.78B | 4.47B | |
| P/E ratio | -33.62 | -60.84 | -37.31 | -33.61 | -0.28 | |
| Price to sales ratio | 7.81 | 10.87 | 16.54 | 7.09 | 1.59 | |
| POCF ratio | -671.59 | 201.37 | -338.22 | 74.28 | 20.17 | |
| PFCF ratio | -246.02 | 317.09 | -227.5 | 110.8 | 231.03 | |
| P/B Ratio | 3.22 | 5.93 | 1.14 | 0.9 | 1.65 | |
| PTB ratio | 3.22 | 5.93 | 1.14 | 0.9 | 1.65 | |
| EV to sales | 7.79 | 10.78 | 17.21 | 7.27 | 1.86 | |
| Enterprise value over EBITDA | -107.2 | -206.65 | -55.37 | -1.04K | 0.33 | |
| EV to operating cash flow | -669.68 | 199.73 | -351.89 | 76.21 | 23.63 | |
| EV to free cash flow | -245.32 | 314.51 | -236.7 | 113.68 | 270.67 | |
| Earnings yield | -0.03 | -0.02 | -0.03 | -0.03 | -3.58 | |
| Free cash flow yield | 0 | 0 | 0 | 0.01 | 0 | |
| Debt to equity | 0.41 | 0.46 | 0.09 | 0.08 | 0.69 | |
| Debt to assets | 0.27 | 0.29 | 0.08 | 0.07 | 0.37 | |
| Net debt to EBITDA | 0.31 | 1.7 | -2.15 | -26.19 | 0.05 | |
| Current ratio | 8.53 | 6.52 | 3.19 | 3.7 | 3.29 | |
| Interest coverage | -2.71 | -2.54 | -6.91 | -2.97 | 1.42K | |
| Income quality | 0.05 | -0.3 | 0.11 | -0.45 | -0.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.28 | 0.3 | 0.46 | 0.22 | 0.19 | |
| Research and developement to revenue | 0.13 | 0.12 | 0.15 | 0.15 | 0.14 | |
| Intangibles to total assets | 0.64 | 0.61 | 0.94 | 0.93 | 0.67 | |
| Capex to operating cash flow | 1.73 | -0.36 | 0.49 | -0.33 | -0.91 | |
| Capex to revenue | -0.02 | -0.02 | -0.02 | -0.03 | -0.07 | |
| Capex to depreciation | -0.24 | -0.24 | -0.33 | -0.29 | -0.64 | |
| Stock based compensation to revenue | 0.1 | 0.12 | 0.43 | 0.15 | 0.09 | |
| Graham number | 22.59 | 20.9 | 145.48 | 79.28 | 164.95 | |
| ROIC | -0.05 | -0.04 | -0.02 | -0.02 | 3.36 | |
| Return on tangible assets | -0.18 | -0.16 | -0.42 | -0.32 | -9.52 | |
| Graham Net | -0.07 | -0.4 | -10.27 | -4.01 | -5.78 | |
| Working capital | 470.3M | 497.82M | 726.96M | 894.43M | 915.62M | |
| Tangible asset value | 28.53M | 42.49M | -718.32M | -368.7M | -602.21M | |
| Net current asset value | 16.98M | -800K | -811.87M | -463.41M | -722.22M | |
| Invested capital | 0.41 | 0.46 | 0.09 | 0.08 | 0.69 | |
| Average receivables | 35.33M | 50.26M | 113.11M | 169.12M | 189.76M | |
| Average payables | 5.83M | 8.42M | 27.55M | 46.64M | 47.47M | |
| Average inventory | 0 | 0 | 28.25M | 64.79M | 64.71M | |
| Days sales outstanding | 38.05 | 37.57 | 56.48 | 30.34 | 31.93 | |
| Days payables outstanding | 22.03 | 17.96 | 42.99 | 26.53 | 23.4 | |
| Days of inventory on hand | 0 | 0 | 52.76 | 41.02 | 27.64 | |
| Receivables turnover | 9.59 | 9.72 | 6.46 | 12.03 | 11.43 | |
| Payables turnover | 16.57 | 20.33 | 8.49 | 13.76 | 15.6 | |
| Inventory turnover | 0 | 0 | 6.92 | 8.9 | 13.2 | |
| ROE | -0.1 | -0.1 | -0.03 | -0.03 | -5.92 | |
| Capex per share | -0.13 | -0.15 | -0.29 | -0.41 | -1.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.67 | 3.78 | 3.93 | 3.86 | 3.97 | |
| Net income per share | -19.22 | -0.45 | -23.49 | -0.42 | -0.4 | |
| Operating cash flow per share | 0.57 | 0.39 | 0.4 | 0.08 | 0.62 | |
| Free cash flow per share | 0.3 | 0.12 | 0.07 | -0.2 | 0.39 | |
| Cash per share | 5.48 | 5.56 | 5.66 | 5.45 | 5.84 | |
| Book value per share | 37.7 | 37.42 | 14.23 | 14.06 | 13.98 | |
| Tangible book value per share | -4 | -4 | -3.71 | -3.67 | -3.42 | |
| Share holders equity per share | 37.7 | 37.42 | 14.23 | 14.06 | 13.98 | |
| Interest debt per share | 9.88 | 9.83 | 9.77 | 9.71 | 9.69 | |
| Market cap | 5.36B | 4.1B | 3.84B | 4.22B | 4.16B | |
| Enterprise value | 6.06B | 4.78B | 4.49B | 4.9B | 4.77B | |
| P/E ratio | -0.43 | -13.95 | -0.25 | -15.24 | -15.94 | |
| Price to sales ratio | 9.05 | 6.71 | 6.01 | 6.71 | 6.37 | |
| POCF ratio | 57.96 | 65.05 | 58.51 | 320.74 | 41.08 | |
| PFCF ratio | 112.52 | 206.89 | 328.99 | -129.96 | 64.34 | |
| P/B Ratio | 0.88 | 0.68 | 1.66 | 1.84 | 1.81 | |
| PTB ratio | 0.88 | 0.68 | 1.66 | 1.84 | 1.81 | |
| EV to sales | 10.22 | 7.81 | 7.04 | 7.79 | 7.31 | |
| Enterprise value over EBITDA | -3.08K | -761.19 | 1.17 | 200.05 | 153.21 | |
| EV to operating cash flow | 65.49 | 75.78 | 68.51 | 372.7 | 47.16 | |
| EV to free cash flow | 127.14 | 241 | 385.18 | -151.02 | 73.85 | |
| Earnings yield | -0.58 | -0.02 | -0.99 | -0.02 | -0.02 | |
| Free cash flow yield | 0.01 | 0 | 0 | -0.01 | 0.02 | |
| Debt to equity | 0.26 | 0.26 | 0.69 | 0.69 | 0.69 | |
| Debt to assets | 0.2 | 0.2 | 0.37 | 0.37 | 0.37 | |
| Net debt to EBITDA | -354.39 | -107.73 | 0.17 | 27.89 | 19.75 | |
| Current ratio | 3.38 | 3.13 | 3.29 | 3.37 | 3.45 | |
| Interest coverage | -14.68 | -52.11 | -1.98K | 13.43 | -8.17 | |
| Income quality | -0.03 | -0.86 | -0.02 | -0.19 | -1.55 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.19 | 0.18 | 0.19 | 0.18 | 0.21 | |
| Research and developement to revenue | 0.14 | 0.14 | 0.13 | 0.14 | 0.13 | |
| Intangibles to total assets | 0.83 | 0.83 | 0.67 | 0.67 | 0.66 | |
| Capex to operating cash flow | -0.48 | -0.69 | -0.82 | -3.47 | -0.36 | |
| Capex to revenue | -0.08 | -0.07 | -0.08 | -0.07 | -0.06 | |
| Capex to depreciation | -0.71 | -0.66 | -0.68 | -0.62 | -0.46 | |
| Stock based compensation to revenue | 0.09 | 0.09 | 0.08 | 0.07 | 0.09 | |
| Graham number | 127.69 | 19.56 | 86.73 | 11.6 | 11.17 | |
| ROIC | -0.01 | -0.01 | 0.95 | -0.01 | -0.01 | |
| Return on tangible assets | -2.26 | -0.05 | -2.65 | -0.05 | -0.04 | |
| Graham Net | -5.89 | -6 | -5.76 | -5.8 | -5.39 | |
| Working capital | 885.79M | 876.19M | 915.62M | 905.36M | 937.57M | |
| Tangible asset value | -645.72M | -647.6M | -602.21M | -597.91M | -562.15M | |
| Net current asset value | -760.86M | -763.72M | -722.22M | -731.21M | -700.3M | |
| Invested capital | 0.26 | 0.26 | 0.69 | 0.69 | 0.69 | |
| Average receivables | 198.48M | 203.57M | 206.13M | 213.27M | 215.58M | |
| Average payables | 70.89M | 82.58M | 59.24M | 43.16M | 27.35M | |
| Average inventory | 65.46M | 59.8M | 57.84M | 51.07M | 39.93M | |
| Days sales outstanding | 31.21 | 29.69 | 29.72 | 30.89 | 29.68 | |
| Days payables outstanding | 46.55 | 34.32 | 22.72 | 18.29 | 7.59 | |
| Days of inventory on hand | 29.72 | 28.77 | 26.85 | 21.68 | 16.09 | |
| Receivables turnover | 2.88 | 3.03 | 3.03 | 2.91 | 3.03 | |
| Payables turnover | 1.93 | 2.62 | 3.96 | 4.92 | 11.86 | |
| Inventory turnover | 3.03 | 3.13 | 3.35 | 4.15 | 5.6 | |
| ROE | -0.51 | -0.01 | -1.65 | -0.03 | -0.03 | |
| Capex per share | -0.28 | -0.27 | -0.33 | -0.28 | -0.22 |
TDOC Frequently Asked Questions
What is Teladoc Health, Inc. stock symbol ?
Teladoc Health, Inc. is a US stock , located in Purchase of Ny and trading under the symbol TDOC
Is Teladoc Health, Inc. buy or a sell ?
43 stock analysts have 43 predictions with a medium analyst target price of $63.95. The lowest prediction is $25 and the highest is $150
What is TDOC stock prediction ?
What is Teladoc Health, Inc. stock quote today ?
Teladoc Health, Inc. stock price is $19.05 today.
Is Teladoc Health, Inc. stock public?
Yes, Teladoc Health, Inc. is a publicly traded company.
Company Profile
- Volume Average 5.43M
- Market Capitalization 3.1B
- Employee 4.82K
- CEO Mr. Jason Nathanial Gorevic
- Headquarters Purchase,NY,US
- IPO Date 2015-06-30
-
Website
https://www.teladochealth.com 
Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
